Long-Covid: What Awaits Us After Corona Infection?

Abstract

Purpose: Studies show that the effects of Covid-19 disease sometimes last for months. The condition of observing the symptoms that continue 28 days after the Covid-19 disease is called “Long-Corona Syndrome” This study was carried out to determine the presence, frequency and affecting factors of symptoms that continue after 28 days in patients with mild course of Covid-19 disease. Methods: This study was carried out to determine the symptoms and affecting factors after 28 days in patients who had a mild course of Covid-19 and recovered. 64 thousand Covid-19 patients were diagnosed in our city until July 2021. A survey was conducted by contacting 659 people who did not have an indication for hospitalization, either face-to-face or by telephone. 635 people completed the survey. Results: The mean age of the patients was 44.26±15.69 years, 50.10% were female and 43.50% were university graduates. It was determined that an average of 6.39±2.61 months (min:2; max:14) had passed since the patients were diagnosed with Covid-19. The most common symptoms of fatigue were muscle pain, memory problems, joint pain, and smell disorders, respectively. It was found that there was a significant relationship between the presence of persisting symptoms, the observation of symptoms at the beginning of the disease, the presence of lung involvement, the status of taking anticoagulants, and the prolongation of the recovery time of active symptoms (p<0.05). Female gender, presence of chronic disease and non-vaccination were observed at higher rates in Long-Covid patients. Conclusion: Persisting symptoms are observed more in patients with severe clinical course of Covid-19 disease. As vaccination rates increase, the rate of observing persisting symptoms decreases. There is a need for further research on this subject with more vaccinated individuals.

Keywords

• COVİD-19
• Long-Covid
• Persisting symptoms
• Post-Covid-19 Syndrome

Project Number

Yok

References

1. Sheng WH, Ko WC, Huang YC, Hsueh PR. SARS-CoV-2 and COVID-19. J Microbiol Immunol Infect. 2020;53(3):363-364. doi:10.1016/j.jmii.2020.03.033
2. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365-367. doi:10.1016/j.jmii.2020.02.001
3. Decaro N, Lorusso A. Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses. Vet Microbiol. 2020;244:108693. doi:10.1016/j.vetmic.2020.108693
4. World Health Organization (WHO). Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int/ (accessed 27 January 2021).
5. Naserghandi A, Allameh SF, Saffarpour R. All about COVID-19 in brief. New Microbes New Infect. 2020;35:100678. Published 2020 Apr 13. doi:10.1016/j.nmni.2020.100678
6. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8
7. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X
8. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. doi:10.1208/s12248-020-00532-2

9. Sreepadmanabh M, Sahu AK, Chande A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. J Biosci. 2020;45(1):148. doi:10.1007/s12038-020-00114-6
10. Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;170:1-25. doi:10.1016/j.addr.2020.12.011
11. 1Lv H, Wu NC, Mok CKP. COVID-19 vaccines: Knowing the unknown. Eur J Immunol. 2020;50(7):939-943. doi:10.1002/eji.202048663
12. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi:10.1136/bmj.n136
13. Garg P, Arora U, Kumar A, Wig N. The "post-COVID" syndrome: How deep is the damage?. J Med Virol. 2021;93(2):673-674. doi:10.1002/jmv.26465
14. Mendelson M, Nel J, Blumberg L, et al. Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10-12. doi:10.7196/SAMJ.2020.v111i11.15433
15. Mahase E. Covid-19: What do we know about "long covid"?. BMJ. 2020;370:m2815. doi:10.1136/bmj.m2815
16. Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426. doi:10.1016/j.socscimed.2020.113426
17. The Lancet. Facing up to long COVID. Lancet. 2020;396(10266):1861. doi:10.1016/S0140-6736(20)32662-3
18. Mandal S, Barnett J, Brill SE, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396-398. doi:10.1136/thoraxjnl-2020-215818
19. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):e63-e67. doi:10.7861/clinmed.2020-0896
20. Fernández-de-Las-Peñas C, Florencio LL, Gómez-Mayordomo V, Cuadrado ML, Palacios-Ceña D, Raveendran AV. Proposed integrative model for post-COVID symptoms. Diabetes Metab Syndr. 2021;15(4):102159. doi:10.1016/j.dsx.2021.05.032
21. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol. 2021;12:686029. doi:10.3389/fimmu.2021.686029
22. LongCovidSOS. Prime Minister Boris Johnson, respond to our SOS. Available from: https://www.longcovidsos.org/ (accessed 27 January 2021).
23. Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020;ciaa1792. doi:10.1093/cid/ciaa1792
24. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10(6):763. doi:10.3390/pathogens10060763
25. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830
26. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603
27. El Sayed S, Shokry D, Gomaa SM. Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period. Neuropsychopharmacol Rep. 2021;41(1):50-55. doi:10.1002/npr2.12154
28. Willi S, Lüthold R, Hunt A, et al. COVID-19 sequelae in adults aged less than 50 years: A systematic review. Travel Med Infect Dis. 2021;40:101995. doi:10.1016/j.tmaid.2021.101995
29. Karaarslan F, Demircioğlu Güneri F, Kardeş S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. Rheumatol Int. 2021;41(7):1263-1271. doi:10.1007/s00296-021-04882-8
30. Bakılan F, Gökmen İG, Ortanca B, et al. Musculoskeletal symptoms and related factors in postacute COVID-19 patients. Int J Clin Pract. 2021;e14734. doi:10.1111/ijcp.14734
31. Sigal LH. What is causing the 'long-hauler' phenomenon after COVID-19?. Cleve Clin J Med. 2021;88(5):273-278. doi:10.3949/ccjm.88a.21009
32. Klein H, Asseo K, Karni N, et al. Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients. MedRxiv [preprint] 2020. 2020.09.25.20201343. doi:10.1101/2020.09.25.20201343.
33. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management [published correction appears in BMJ. 2021 Aug 3;374:n1944]. BMJ. 2021;374:n1648. doi:10.1136/bmj.n1648
34. Ritchie K, Chan D, Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage?. Brain Commun. 2020;2(2):fcaa069. doi:10.1093/braincomms/fcaa069
35. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4-e6. doi:10.1016/j.jinf.2020.08.029
36. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020;83(2):680-682. doi:10.1016/j.jaad.2020.05.079